JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Aandelen Lijst・Gossamer Bio Inc

Gossamer Bio Inc

Gesloten

SectorGezondheidszorg

0.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.35

Max

0.36

Belangrijke statistieken
By Trading Economics
Inkomsten	983K -47M
Verkoop	505K 14M
Winstmarge	-342.329
Werknemers	161
EBITDA	-346K -46M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+1122.22% upside

Dividenden
By Dow Jones
Volgende Winsten	14 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7M 99M
Vorige openingsprijs	0.36
Vorige sluitingsprijs	0.36

Nieuwssentiment

By Acuity

72%

28%

328 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

1.06 / 1.23 Steun & Weerstand

Gossamer Bio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 19:19 UTC

Acquisities, Fusies, Overnames

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Winsten

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Winsten

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Winsten

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Marktinformatie

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisities, Fusies, Overnames

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisities, Fusies, Overnames

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Marktinformatie

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Marktinformatie

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Winsten

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Winsten

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Marktinformatie

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Marktinformatie

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Marktinformatie

Winsten

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Winsten

Acquisities, Fusies, Overnames

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Winsten

Acquisities, Fusies, Overnames

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Gossamer Bio Inc Prognose

Koersdoel

By TipRanks

1122.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.4 USD 1122.22%

Hoogste 15 USD

Laagste 0.3 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gossamer Bio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Gossamer Bio Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.06 / 1.23Steun & Weerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

328 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.